Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03474497
Title Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of California, Davis
Indications

head and neck squamous cell carcinoma

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Aldesleukin + Pembrolizumab + Radiotherapy

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.